webinar register page

Webinar banner
EPPIC Global Presents: Role of AI/ML in transforming and accelerating drug discovery process


Oct 17, 2020 02:04 PM

Webinar logo
* Required information

By registering, I agree to the Privacy Statement and Terms of Service.



Stacie Calad-Thomson
Stacie Calad-Thomson, PhD is an experienced pharma R&D and biotech leader with expertise in AI and ML applications to drug discovery. She has led collaborations and partnerships in the AI drug discovery space, most recently as VP, Head of Artificial Intelligence Molecular Screen (AIMS) Partnerships at Atomwise. Previously, she established and was Co-lead of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium. ATOM is a public-private partnership developing machine learning tools to accelerate drug discovery and founding members include GSK, UCSF, the Department of Energy’s Lawrence Livermore National Laboratory, and the National Cancer Institute’s Frederick National Laboratory for Cancer Research. She worked at GSK for 13+ years, starting as a process chemist then moving into R&D strategy and operations roles where she led several change initiatives and teams. Stacie has a B.S. in Chemistry from UC Berkeley and a Ph.D. in chemistry from UC Irvine.
Sharath Hegde
CSO @Recursion Pharmaceutical
Sharath has more than 30 years of drug-discovery experience, all of it in the San Francisco Bay Area biotech hub. He has participated in the discovery of numerous New Chemical Entities (NCE), including the marketed medicines Yupelri®, Vibativ® and several others in different stages of clinical development. Prior to joining Recursion, Sharath spent 19 years at Theravance Biopharma where he was Senior Vice President, Research. Before Theravance, Sharath spent 9 years at Syntex Corporation, later acquired by Roche Holdings, Ltd. Sharath obtained his Ph.D. in Pharmacology from the University of Houston and his B.Pharm and M.Pharm from the University of Mumbai. Sharath loves reading, the outdoors and collecting antique medicine containers.
Gini Deshpande
PhD @NuMedii, Inc.
Gini Deshpande is a scientist, entrepreneur and angel investor. She has over 20 years of experience translating cutting edge life sciences technologies into products. As founder and CEO of NuMedii, she pioneered the field of AI driven drug discovery, helped develop the company's core technology, structured critical partnerships and raised the Company's initial rounds of financing from two leading Bay Area VC firms. Previously, as a consultant, she helped early stage platform companies identify optimal markets, enabling them to raise over $25M in financing. At Affymetrix, she was responsible for new product opportunities for their largest segment. As Director of an early stage business at Children’s Hospital Boston, she secured grant funding for six medical device products. She has also managed broad, diverse IP portfolios and closed licensing deals worth several million. She received her PhD in Biological Sciences from Purdue University and did post-doc work at Harvard Medical School.